WMIS Presents 2018 Commercial Innovation of the Year Award to MILabs for VECTor-6 Broadband Photon Tomography
The World Molecular Imaging Society (WMIS) presented the 4th annual Commercial Innovation of the Year Award to Netherlands-based molecular imaging company MILabs at the 2018 World Molecular Imaging Congress in Seattle in September. MILabs was recognized for its latest innovation, VECTor-6 Broadband Photon Tomography, presented by Frederik Beekman, CEO/CSO, MILabs.
CULVER CITY, Calif., October 15, 2018 /PRNewswire-PRWeb/ -- The World Molecular Imaging Society (WMIS) presented the 4th annual Commercial Innovation of the Year Award to Netherlands-based molecular imaging company MILabs at the 2018 World Molecular Imaging Congress in Seattle in September. MILabs was recognized for its latest innovation, VECTor-6 Broadband Photon Tomography, presented by Frederik Beekman, CEO/CSO, MILabs.
The WMIS community chooses the winner of the Commercial Innovation of the Year Award each year following presentations from 4-6 finalists at WMIC. In addition to winning the 2018 award, MILabs was the recipient of the first-ever Commercial Innovation of the Year Award at WMIC 2015 in Hawaii for work in SPECT imaging.
MILabs' VECTor-6 enables researchers to perform an almost unlimited number of novel experiments for new discoveries. This technology has the ability to image many molecules at dramatically enhanced resolution than those before it to perform combined imaging of thousands of new combinations of tracers.
VECTor-6 Broadband Photon Tomography is able to detect several important PET isotopes that could not be imaged in a mouse at a sufficient resolution to quantify or clearly visualize uptake in tissue - it can now be imaged at sub-mm resolution, with about 3 times better resolution than state of-the-art coincidence PET. The technology also provides the ability to simultaneously image thousands of tracer combinations including PET/PET and PET/SPECT mixtures. In addition, new ultra-high resolution CT and Optical Imaging modules have been integrated that offers extremely high performance characteristics for in-vivo imaging.
"It's great that this award brings the VECTor-6 platform in the spotlight, so that both academics and pharmaceutical industry researchers can become aware that new imaging options are now available that extend applications beyond the capabilities of conventional PET, SPECT, Optical and CT imaging," said Beekman. "My team is very proud and happy about this recognition and the fact they are contributing to potentially raising biomedical research to new levels by building top-of-the-line instruments."
The 2018 runner-up was Bruker Española SA for its work in fostering a new novel method for MRI-derived PET gating for cardiac imaging and motion correction. The 5th annual Commercial Innovation of the Year Award will be given in Montréal, Québec, Canada at WMIC 2019. Abstracts will be accepted beginning December 1, 2018.
ABOUT MILABS
MILabs was founded in 2006 as an in-vivo imaging spin-off from the University Medical Centre Utrecht, the Netherlands. Today, the company is one of the global leaders in molecular imaging with the development of preclinical PET, SPECT, CT and Optical imaging systems and human SPECT scanners. These imaging systems have received many international awards from the molecular imaging community and support the research of hundreds of satisfied users worldwide. Several hundreds of peer-reviewed scientific papers have already been published to document the use of MILabs' multimodal imaging systems for SPECT, PET, CT, Autoradiography as well as bioluminescence, fluorescence and Cherenkov imaging applications. MILabs imaging systems provide simple, intuitive system operation and highly efficient workflow.
ABOUT WORLD MOLECULAR IMAGING SOCIETY
The WMIS is dedicated to developing and promoting translational research through multimodality molecular imaging. The education and abstract-driven WMIC is the annual meeting of the WMIS and provides a unique setting for scientists and clinicians with very diverse backgrounds to interact, present, and follow cutting-edge advances in the rapidly expanding field of molecular imaging that impacts nearly every biomedical discipline. Industry exhibits at the congress included corporations who have created the latest advances in preclinical and clinical imaging approaches and equipment, providing a complete molecular imaging educational technology showcase. For more information: http://www.wmis.org
SOURCE WMIS-World Molecular Imaging Society
Share this article